Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company whose news flow centers on its TGF-ß pathway–focused pipeline, corporate strategy and capital allocation decisions. The company’s disclosures describe a focus on developing protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, with particular emphasis on neuromuscular and hematologic conditions.
News about Keros frequently highlights clinical development milestones for its lead product candidate, KER-065, which is being developed for neuromuscular diseases with an initial focus on Duchenne muscular dystrophy. Recent updates have included Phase 1 clinical data in healthy volunteers, additional analyses of bone and muscle-related endpoints, and U.S. Food and Drug Administration Orphan Drug designation for KER-065 in DMD. Investors following KROS news can expect coverage of trial design, safety and pharmacodynamic findings, and plans for subsequent clinical phases.
Another recurring theme in Keros news is progress related to elritercept, the company’s most advanced product candidate for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis. The company has reported developments under its global license agreement with Takeda Pharmaceuticals U.S.A., Inc., including Takeda’s plans to advance elritercept into a Phase 3 clinical trial in first-line myelodysplastic syndromes.
Keros’ news flow also includes corporate and financial updates. These have covered a strategic realignment to prioritize KER-065, discontinuation of internal development of cibotercept (KER-012), leadership and board changes, and a substantial capital return program involving stock repurchase agreements and a cash tender offer for a significant portion of its outstanding common stock. Earnings releases and Form 8-K filings provide additional context on financial results, cash position and the execution of the capital return plan.
For investors and observers, the KROS news page offers a consolidated view of clinical trial announcements, regulatory designations, partnership developments, governance changes and capital allocation actions that shape the company’s trajectory. Regular review of these updates can help track how Keros advances its TGF-ß–focused pipeline and manages its resources over time.
Keros Therapeutics, Inc. (KROS) presented data from its Phase 1 clinical trial of KER-047 at the 62nd ASH Annual Meeting, highlighting significant increases in serum iron and transferrin saturation with a corresponding decrease in ferritin and hepcidin. Preclinical data also revealed that KER-050 could alleviate anemia through various mechanisms. The Phase 1 trial showed a tolerability profile with no serious adverse events, although some mild to moderate adverse events were reported. Keros plans to initiate Phase 2 trials for both KER-050 and KER-047 in 2021.
Keros Therapeutics, Inc. (KROS) has successfully closed a public offering of 2,990,000 shares of common stock at $50.00 each, generating $149.5 million in gross proceeds. This offering included the full exercise of the underwriters' option to purchase an additional 390,000 shares. The offering was managed by Jefferies LLC, SVB Leerink LLC, and Piper Sandler & Co. The proceeds will be used to advance Keros’ clinical programs, including its lead product candidates KER-050, KER-047, and KER-012, which target hematological and musculoskeletal disorders.
Keros Therapeutics, a clinical-stage biopharmaceutical company, will have its President and CEO, Jasbir S. Seehra, present at the Jefferies Virtual London Healthcare Conference on November 18 at 9:05 am ET. The event will be webcast live and archived on the company's website for 90 days. Keros focuses on developing treatments for hematological and musculoskeletal disorders with high unmet medical needs, including its lead product candidates KER-050, KER-047, and KER-012, targeting conditions like anemia and osteoporosis.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced a public offering of 2,600,000 shares at $50.00 each, aiming to raise $130 million before expenses. The offering, managed by Jefferies LLC, SVB Leerink LLC, and Piper Sandler & Co., is set to close on November 17, 2020. The company also granted underwriters a 30-day option for an additional 390,000 shares. Keros focuses on developing novel treatments for hematological and musculoskeletal disorders, with lead candidates including KER-050 and KER-047 targeting conditions like anemia and bone loss.
Keros Therapeutics (Nasdaq: KROS) announced a proposed underwritten public offering of 2,250,000 shares of common stock, with an option for underwriters to purchase an additional 337,500 shares. Pricing details are yet to be determined, as the offering is subject to market conditions. Jefferies LLC, SVB Leerink LLC, and Piper Sandler & Co. are managing the offering, while a registration statement has been filed with the SEC but is not yet effective. Keros focuses on developing treatments for hematological and musculoskeletal disorders.
Keros Therapeutics (KROS) reported Q3 2020 financial results and a business update, achieving a milestone by dosing first patients in its Phase 2 clinical trial for KER-050, targeting myelodysplastic syndromes. The company regained worldwide rights to metabolic disease programs following the termination of its collaboration with Novo Nordisk, effective April 2021. Keros reported a net loss of $12.0 million for Q3 2020, up from $3.5 million in Q3 2019, driven by increased R&D and administrative expenses. Cash reserves at the end of Q3 stood at $133.8 million, projected to sustain operations into late 2022.
Keros Therapeutics (Nasdaq: KROS) announced four abstracts related to its KER-050 and KER-047 programs will be presented at the virtual 62nd American Society of Hematology Annual Meeting from December 5-8, 2020. Key presentations include:
1. KER-050's role in promoting erythroid differentiation (Publication Number: 2736).
2. KER-050 alleviating cytopenia (Publication Number: 2582).
3. KER-047's effects on serum iron (Publication Number: 769).
4. KER-047 inhibiting ALK2 signaling (Publication Number: 771). These programs target significant hematological disorders with high unmet medical needs.
Keros Therapeutics has initiated a Phase 2 clinical trial for KER-050, targeting anemia and thrombocytopenia in patients with myelodysplastic syndromes (MDS). The first two participants have been dosed, with initial data expected by mid-2021. This open-label trial aims to confirm KER-050's safety and tolerability in patients with varying risks of MDS. Results from prior Phase 1 trials showed a robust hematological response in healthy volunteers. KER-050 could potentially address the significant unmet medical needs in MDS, affecting up to 170,000 patients annually in the U.S.
Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that CEO Jasbir S. Seehra, Ph.D., will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 10:30 am ET. Keros specializes in developing novel treatments for hematological and musculoskeletal disorders with high unmet needs. Its lead candidates include KER-050 for cytopenias, KER-047 for anemia and fibrodysplasia ossificans progressiva, and KER-012 for bone loss disorders and pulmonary arterial hypertension.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced positive preclinical results for KER-012 during the ASBMR 2020 Annual Meeting. KER-012, an activin receptor type II ligand trap, significantly increased trabecular bone volume in mice by reducing catabolism and enhancing anabolism. Key findings showed an 82.0% rise in bone volume and significant increases in trabecular thickness and formation rates. KER-012 aims to address conditions like osteoporosis, with potential implications for treating cancer-induced bone loss. CEO Jasbir S. Seehra highlighted the unique mechanism of KER-012 as a significant advancement in bone health treatments.
FAQ
What is the current stock price of Keros Therapeutics (KROS)?
What is the market cap of Keros Therapeutics (KROS)?
